Developing a patient-centred tool for pain measurement and evaluation in autosomal dominant polycystic kidney disease

Background. Pain affects 60% of the autosomal dominant polycystic kidney disease (ADPKD) population. Despite being an early and debilitating symptom, it is poorly characterized and management is suboptimal. This study aimed to develop an ADPKD-specific pain assessment tool (APAT) to facilitate pain research. Methods. Following a systematic review of PATs used in ADPKD studies and against international recommendations for pain trials, our multi-disciplinary team of clinical experts and patients constructed an ADPKD-pain conceptual framework of key pain evaluation themes. We compiled a new APAT covering domains prioritized within our framework using components of questionnaires validated in other chronic pain disorders. The APAT was administered longitudinally within a randomized high-water intake trial (NCT02933268) to ascertain feasibility and provide pilot data on ADPKD pain. Results. Thirty-nine ADPKD participants with chronic kidney disease Stages 1-4 provided 129 APAT responses. Each participant completed a median of 3 (range 1-10) assessments. Respondents' mean standard deviation age was 47 +/- 13years; 59% (23) were female; and 69% (27) had enlarged kidneys with median time from diagnosis 14.2 (interquartile range 7.0-25.9) years. Pain (52%) and associated analgesic use (29%) were common. Pain severity was associated with increasing age [odds ratio (OR) = 1.07, P=0.009], female gender (OR = 4.34, P=0.018), estimated glomerular filtration rate<60mL/min/1.73m(2) (OR = 5.45, P=0.021) and hypertension (OR = 12.11, P=0.007), but not with kidney size (P=0.23). The APAT achieved good internal consistency (Cronbach's alpha coefficient=0.91) and test-retest reliability (domain intra-class correlation coefficients ranging from 0.62 to 0.90). Conclusions. The APAT demonstrated good acceptability and reliability, and following further validation in a larger cohort could represent an invaluable tool for future ADPKD pain studies.